MAP1LC3A Human shRNA Plasmid Kit (Locus ID 84557)
CAT#: TL303356
MAP1LC3A - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector, 5µg of each construct provided
Need custom shRNA service?
Get a free quote
CNY 7,740.00
Product images
![](https://cdn.origene.com/img/defaults-img.jpg)
CNY 4,070.00
Specifications
Product Data | |
Product Name | MAP1LC3A Human shRNA Plasmid Kit (Locus ID 84557) |
Locus ID | 84557 |
UniProt ID | Q9H492 |
Synonyms | ATG8E; LC3; LC3A; MAP1ALC3; MAP1BLC3 |
Vector | pGFP-C-shLenti |
Format | Lentiviral plasmids |
Kit Components | MAP1LC3A - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 84557). 5µg purified plasmid DNA per construct29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free. |
RefSeq | NM_032514, NM_181509, NM_032514.1, NM_032514.2, NM_032514.3, NM_181509.1, NM_181509.2, BC015810, BC015810.1, BM740344, BM919877, NM_181509.3, NM_032514.4 |
Summary | MAP1A and MAP1B are microtubule-associated proteins which mediate the physical interactions between microtubules and components of the cytoskeleton. MAP1A and MAP1B each consist of a heavy chain subunit and multiple light chain subunits. The protein encoded by this gene is one of the light chain subunits and can associate with either MAP1A or MAP1B. Two transcript variants encoding different isoforms have been found for this gene. The expression of variant 1 is suppressed in many tumor cell lines, suggesting that may be involved in carcinogenesis. [provided by RefSeq, Feb 2012] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Documents
Product Manuals |
FAQs |
SDS |
其它MAP1LC3A产品